Vaxcyte/$PCVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Ticker
$PCVX
Sector
Primary listing
Employees
507
Headquarters
Website
Vaxcyte Metrics
BasicAdvanced
$8.4B
-
-$5.63
1.34
-
Price and volume
Market cap
$8.4B
Beta
1.34
52-week high
$76.61
52-week low
$27.66
Average daily volume
1.6M
Financial strength
Current ratio
7.909
Quick ratio
7.813
Long term debt to equity
4.147
Total debt to equity
4.375
Profitability
EBITDA (TTM)
-907.279
Management effectiveness
Return on assets (TTM)
-17.72%
Return on equity (TTM)
-25.59%
Valuation
Price to book
2.84
Price to tangible book (TTM)
2.84
Price to free cash flow (TTM)
-11.123
Free cash flow yield (TTM)
-8.99%
Free cash flow per share (TTM)
-5.236
Growth
Earnings per share change (TTM)
48.14%
3-year earnings per share growth (CAGR)
17.82%
What the Analysts think about Vaxcyte
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Vaxcyte Financial Performance
Revenues and expenses
Vaxcyte Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vaxcyte stock?
Vaxcyte (PCVX) has a market cap of $8.4B as of March 11, 2026.
What is the P/E ratio for Vaxcyte stock?
The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of March 11, 2026.
Does Vaxcyte stock pay dividends?
No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of March 11, 2026.
When is the next Vaxcyte dividend payment date?
Vaxcyte (PCVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxcyte?
Vaxcyte (PCVX) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.